Letters to the Editor

Letters to the Editor are no longer included in the main BJUI journal, but we will continue to publish them on the BJUI website as an important part of the scientific debate.

Letters Policy

  • Letters to the editor will now published in electronic form on the journal website (www.bjuinternational.com), not in the journal itself. As such, letters are not submitted to PubMed for indexing.
  • Letters to the editor should be 500 words or less, preference is given to concise letters.
  • Writers are limited to one letter published on the website per month.
  • Letters must include full author contact details.
  • All letters will be peer-reviewed, and we reserve the right to reject letters, or to edit them if they are accepted.
  • If accepted, letters are sent to the authors of the paper being discussed, to give them the chance to make a response that will (if accepted) be published at the same time as the letter.
  • Letters will not be open for public comment; replies must be submitted by email to the Editorial Office for review.

Clinical and sonographic features predict testicular torsion in children: a prospective study

Sir, We read the recent publication on clinical and sonographic features predicting testicular torsion in children with great interest [1]. Boettcher et al. identified a variety of clinical predictors, such as short pain duration, nausea or vomiting, abnormal ipsilateral cremasteric reflex, scrotal skin changes and high position of the testicle, as being associated with an increased likelihood of testiscular torsion. They showed that a clinical scoring system based on these clinical factors would…

To treat or not to treat: is the way forward clearer in low-risk prostate cancer?

Sir, I read with interest the above "Comment" by Dr Gnanapragasam in the August issue of the Journal [1]. While I applaud his efforts at suggesting improvements to the criteria by which a decision is made to manage a patient with prostate cancer on an active surveillance program I feel he distracts from the clear, simple and important message of the PIVOT trial [2]. That message is that if, using the D'Amico criteria [3], a patient is classified as being in a low risk prostate cancer group then…
© 2024 BJU International. All Rights Reserved.